Leo Pharma A/S acquires rights to develop and market Kyntheum for moderate-to-severe psoriasis outside of Europe

Leo Pharma A/S, a global leader in medical dermatology, has announced it has acquired the exclusive rights to develop and market brodalumab (marketed as Kyntheum in the European Union) for the treatment of moderate-to-severe psoriasis outside of Europe through a new sub-licencing agreement with Bausch Health Ireland Limited.

The new agreement includes countries with significantly high unmet need, such as Australia, Brazil, Egypt, Mexico, Russia and Saudi Arabia.This complements the ongoing licensing agreement between LEO Pharma A/S and AstraZeneca to develop and market brodalumab for the treatment of moderate-to-severe psoriasis in Europe. To date, LEO Pharma A/S has successfully launched brodalumab in 18 countries. Outside of the EU, Bausch Health Companies Inc. through a licensing agreement with AstraZeneca, has owned the global commercial rights for brodalumab except in Japan and other Asian countries, where the rights are owned by Kyowa Kirin Co., Ltd.

Comment: Under the new arrangement terms, Bausch Health has granted LEO Pharma A/S an exclusive license to its global rights to brodalumab but continues to hold the rights for the US and Canada.